Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

NCT02944955 is registered in ClinicalTrials.gov with BioLite, Inc. as lead sponsor.

NCT NCT02944955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02944955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Lead sponsor
BioLite, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
December 31, 2028
Enrollment
52 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome (mds)